Artin Bioscience
Artin Bioscience is dedicated to developing therapies for respiratory diseases and immune system allergic reactions, with a focus on conditions such as COPD, PAH, and Severe Asthma. The company employs innovative scientific approaches, novel mechanisms of action, and multiple mechanisms of action from drug combinations to disrupt disease processes. It is involved in clinical trials, patent filings, and has a strong scientific advisory board. Artin Bioscience aims to provide effective, affordable, and systemic treatments for respiratory conditions, leveraging advanced research and strategic collaborations.
Industries
Nr. of Employees
small (1-50)
Artin Bioscience
Products
Clinical-stage multi-mechanism respiratory therapy (PAH candidate)
A drug candidate formulated for pulmonary arterial hypertension intended to reopen occluded pulmonary arteries and improve hemodynamics; formulation complete and manufactured for trials.
Clinical-stage non-steroidal COPD therapy (candidate)
A non-steroidal dual drug inhaled therapy intended to reduce inflammatory cells, inhibit fibrosis and dilate lung vessels to stabilize disease progression; formulations complete and trial protocol prepared.
Targeted IgE inhibitor for peanut allergy (preclinical/clinical candidate)
A designed covalent heterobivalent inhibitor intended to bind peanut-specific IgE and prevent allergen-triggered mast cell degranulation; development aimed at oral, subcutaneous or patch-based delivery.
non-steroid dual drug treatment for COPD
A non-steroid dual drug treatment by Artin Bioscience expected to stop disease progression in COPD by targeting steroid-unresponsive inflammation and smoldering steroid inflammation.
Artin's COPD therapy for Severe Asthma
A drug therapy originally developed for COPD, intended for use in severe asthma treatment to arrest oxidative stress, protect endothelial cells, improve gas exchange, treat bronchoconstriction, arrest structural lung changes, and target eosinophils.
covalent heterobivalent inhibitor (cHBI)
An engineered precision medicine designed to prevent allergic reactions to peanuts by permanently filling the IgE receptor, blocking allergen binding and preventing mast cell histamine release.
Clinical-stage multi-mechanism respiratory therapy (PAH candidate)
A drug candidate formulated for pulmonary arterial hypertension intended to reopen occluded pulmonary arteries and improve hemodynamics; formulation complete and manufactured for trials.
Clinical-stage non-steroidal COPD therapy (candidate)
A non-steroidal dual drug inhaled therapy intended to reduce inflammatory cells, inhibit fibrosis and dilate lung vessels to stabilize disease progression; formulations complete and trial protocol prepared.
Targeted IgE inhibitor for peanut allergy (preclinical/clinical candidate)
A designed covalent heterobivalent inhibitor intended to bind peanut-specific IgE and prevent allergen-triggered mast cell degranulation; development aimed at oral, subcutaneous or patch-based delivery.
non-steroid dual drug treatment for COPD
A non-steroid dual drug treatment by Artin Bioscience expected to stop disease progression in COPD by targeting steroid-unresponsive inflammation and smoldering steroid inflammation.
Artin's COPD therapy for Severe Asthma
A drug therapy originally developed for COPD, intended for use in severe asthma treatment to arrest oxidative stress, protect endothelial cells, improve gas exchange, treat bronchoconstriction, arrest structural lung changes, and target eosinophils.
covalent heterobivalent inhibitor (cHBI)
An engineered precision medicine designed to prevent allergic reactions to peanuts by permanently filling the IgE receptor, blocking allergen binding and preventing mast cell histamine release.
Services
Protocol development, site contracting and management of multi-center Phase II trials for pulmonary indications.
Support for regulatory filings, orphan designation applications and coordination with major regulatory authorities.
Design and development of inhaled combination therapies and coordination of device selection and patent filings.
Animal model development and translational studies for pulmonary diseases to support IND-enabling packages.
Protocol development, site contracting and management of multi-center Phase II trials for pulmonary indications.
Support for regulatory filings, orphan designation applications and coordination with major regulatory authorities.
Design and development of inhaled combination therapies and coordination of device selection and patent filings.
Animal model development and translational studies for pulmonary diseases to support IND-enabling packages.
Expertise Areas
- Clinical trial management for pulmonary indications
- Respiratory therapeutics development (COPD, PAH, severe asthma)
- Inhaled and oral formulation development
- Regulatory strategy and orphan designation
Key Technologies
- Inhaled drug delivery
- Oral systemic delivery
- Subcutaneous and transdermal delivery formats
- Covalent heterobivalent inhibitor design
News & Updates
Drug formulation for PAH is complete, and drugs are ready for trials. Enrollment for Phase 2 trials has started, with orphan designation awarded by the FDA and applications submitted to EMA. One patent has issued, and a second is filed.
All drug formulations are complete. Patent for multi-drug inhaled device pending, with claims expected to be allowed. Trial protocols are complete, and regulatory guidance has been received. The approach targets disease modification, reducing inflammation and exacerbations.
Drug formulation for PAH is complete, and drugs are ready for trials. Enrollment for Phase 2 trials has started, with orphan designation awarded by the FDA and applications submitted to EMA. One patent has issued, and a second is filed.
All drug formulations are complete. Patent for multi-drug inhaled device pending, with claims expected to be allowed. Trial protocols are complete, and regulatory guidance has been received. The approach targets disease modification, reducing inflammation and exacerbations.